Here, we showed that immune cells from patients with ccRCC confer resistance to cabozantinib treatment by upregulating pro-angiogenic factors when VEGF-A and HB-EGF were suppressed. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.